PGI17 COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

The Public ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Public Payer ◽

Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Cost Effectiveness and Resource Allocation ◽

10.1186/1478-7547-11-25 ◽

2013 ◽

Vol 11 (1) ◽

pp. 25 ◽

Cited By ~ 8

Author(s):

Fabio MR Barros ◽

Hugo Cheinquer ◽

Carolina T Tsuchiya ◽

Eduardo AV Santos

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

The Public ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Public Payer ◽

PGI18 COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPE I CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

Value in Health ◽

10.1016/s1098-3015(10)72337-8 ◽

2010 ◽

Vol 13 (3) ◽

pp. A72

Author(s):

FMR Barros ◽

H Cheinquer ◽

LG Borges ◽

E Santos

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Genotype I ◽

The Public ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Public Payer ◽

Cost-Effectiveness Analysis For The Treatmet with Daclatasvir-Asunaprevir in Patients Naive with Chronic Hepatitis C Genotype 1b Without Baseline Ns5a Polymorphisms Under The Public Payer Perspective in Mexico

Value in Health ◽

10.1016/j.jval.2017.08.2915 ◽

2017 ◽

Vol 20 (9) ◽

pp. A931

Author(s):

C Gama ◽

JM Benita ◽

J Celaya

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

The Public ◽

Effectiveness Analysis ◽

Genotype 1B ◽

Payer Perspective ◽

Public Payer

PGI19 COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

Value in Health ◽

10.1016/s1098-3015(10)72338-x ◽

2010 ◽

Vol 13 (3) ◽

pp. A72

Author(s):

FMR Barros ◽

H Cheinquer ◽

LG Borges ◽

E Santos

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis ◽

Payer Perspective ◽

Peginterferon Alfa ◽

Private Payer

PGI18 Treatment of Chronic Hepatitis C Patients with Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting

Value in Health ◽

10.1016/j.jval.2011.08.889 ◽

2011 ◽

Vol 14 (7) ◽

pp. A394-A395

Author(s):

J. Areias ◽

T. Branco ◽

F. Calinas ◽

A. Carvalho ◽

G. Macedo ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis ◽

Peginterferon Alfa ◽

Chronic Hepatitis C Patients

PIN8 COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON (ALFA-2B) WITH RIBAVIRIN COMPARED WITH PEGINTERFERON (ALFA-2A) WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C

Value in Health ◽

10.1016/s1098-3015(11)72807-8 ◽

2010 ◽

Vol 13 (7) ◽

pp. A431

Author(s):

VV Omelyanovsky ◽

MV Avksentieva ◽

I Krysanov ◽

O Ivakhnenko

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis ◽

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C

Alimentary Pharmacology & Therapeutics ◽

10.1046/j.1365-2036.2003.01453.x ◽

2003 ◽

Vol 17 (5) ◽

pp. 687-694 ◽

Cited By ~ 55

Author(s):

M. Buti ◽

M. Medina ◽

M. A. Casado ◽

J. B. Wong ◽

L. Fosbrook ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis ◽

PIN45 COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B BOTH PLUS RIBAVIRIN IN SPAIN

Value in Health ◽

10.1016/s1098-3015(11)72843-1 ◽

2010 ◽

Vol 13 (7) ◽

pp. A438

Author(s):

P Ventayol-Bosch ◽

C Rubio-Terrés ◽

J García-Samaniego ◽

R Planas ◽

R Solà-Lamoglia ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis ◽

Peginterferon Alfa ◽

Chronic Hepatitis C Patients

Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran

Hepatitis Monthly ◽

10.5812/hepatmon.10236 ◽

2013 ◽

Vol 13 (9) ◽

Cited By ~ 1

Author(s):

Alireza Mehrazmay ◽

Seyed-Moayed Alavian ◽

Maziar Moradi-Lakeh ◽

Mahdi Mokhtari Payam ◽

Amir Hashemi-Meshkini ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Low Dose ◽

Thalassemia Major ◽

Effectiveness Analysis ◽

PIN19 THE COST-EFFECTIVENESS ANALYSIS OF COMBINATION OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS COMBINATION OF PEGINTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND

Value in Health ◽

10.1016/s1098-3015(10)62487-4 ◽

2004 ◽

Vol 7 (3) ◽

pp. 356

Author(s):

E Orlewska

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Effectiveness Analysis ◽

Peginterferon Alfa ◽

The Cost